Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names

Health Policy

Volumn 70, Issue 1, 2004, Pages 23-32

  Paraponaris, A ^a,b,c,d   Verger, P ^a,b   Desquins, B ^a,b,d   Villani, P ^a,c   Bouvenot, G ^a,c   Rochaix, L ^c,d   Gourheux, J C ^e   Moatti, J P ^a,c,d  

^a INSERM   (France)

^b OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d IDEP   (France)

^e URML PACA   (France)

Author keywords

General practitioners' knowledge; General practitioners' prescribings; Generic drugs; Incentive rules; International non proprietary names

Indexed keywords

GENERIC DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG INFORMATION; EMPIRICISM; FEMALE; FRANCE; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; MALE; PHYSICIAN ATTITUDE; PRESCRIPTION; SOCIOECONOMICS;

ADULT; DRUGS, GENERIC; FEMALE; FRANCE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MIDDLE AGED; PHYSICIAN INCENTIVE PLANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES;

EID: 4143112341     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.01.008     Document Type: Article

References (54)

1. Garattini L., Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 51:2000;149-162
2. Danzon P.M., Chao L.W. Cross-national price differences for pharmaceuticals: how large and why? Journal of Health Economics. 19:2000;159-195
3. Danzon P.M., Chao LW. Does regulation drive out competition in pharmaceutical markets? Journal of Law Economics. 43:2000;311-357
4. Delnoij D., Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding? Health Policy. 52:2000;157-169
5. Gosden T., Torgerson D.J. The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Policy. 40:1997;103-114
6. Wilson R.P., Hatcher J., Barton S., Walley T. General practice fundholders' prescribing savings in one region of the United Kingdom 1991-1994. Health Policy. 42:1997;29-37
7. Culkin TT, Mendell S. Generic substitution in New Jersey, 1979-1987. American Pharmacology 1989;NS29:25-30.
8. Joyce G.F., Escarce J.J., Solomon M.D., Goldman D.P. Employer drug benefit plans and spending on prescription drugs. JAMA. 288:2002;1733-1739
9. Kasje W.N., Timmer J.W., Boendermaker P.M., Haaijer-Ruskamp F.M. Dutch GPs' perceptions: the influence of out-of-pocket costs on prescribing. Social Science & Medicine. 55:2002;1571-1578
10. Lopez-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 54:2000;87-123
11. CNAMTS. Medic'Am. Les médicaments remboursés par le Régime Général d'Assurance Maladie au cours des années 2000 et 2001. Caisse Nationale d'Assurance Maladie des Travailleurs Salariés, Paris, 2002.
12. Hancher L. Regulating for competition. Government, law, and the pharmaceutical industry in the United Kingdom and France. Oxford: Clarendon Press; 1990.
13. Trumbull J. Institutions and industrial performance: the pharmaceutical sector in France, Germany, Britain, and the US. IPC Working Paper-00-0002, 2000. Massachussets Institute of Technology, Cambridge.
14. Bouvenot G., Villani P., Bouvenot J. Generic drugs in the medical-economic context of drug prescriptions. Presse Medicale. 31:2002;1109-1114
15. Delattre E., Dormont B. Health care demand induced by French self-employed doctors: a microeconomic study based on panel data. Economie et Prevision. 142:2000;137-161
16. Lopez Bastida J., Mossialos E. Pharmaceutical expenditure in Spain: cost and control. International Journal of Health Services. 30:2000;597-616
17. Mott D.A., Cline R.R. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Medical Care. 40:2002;662-674
18. Bower A.D., Burkett G.L. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. The Journal of Family Practice. 24:1987;612-616
19. Balsan D. Analyse des disparités inter-régionales de dépenses de santé. Etudes et Rósultats 2, 2000. Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques. Ministère de l'Emploi et de la Solidarité, Paris.
20. Insee. Bases de données locales Communes Profils. Institut National de la Statistique et des Etudes Economiques, Paris, 2002.
21. Krzanowski W. Principles of multivariate analysis. Oxford: Clarendon Press; 1988.
22. Tilyard M.W., Dovey S.M., Rosenstreich D. General practitioners' views on generic medication and substitution. The New Zealand Medical Journal. 103:1990;318-320
23. McGettigan P., McManus J., O'Shea B., Chan R., Feely J. Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers' concerns. Ireland Medical Journal. 90:1997;146-147
24. IMS-Health. La délivrance de génériques par région. Panel Xponent, Paris, 2001.
25. Banahan B.F. III, Kolassa E.M. A physician survey on generic drugs and substitution of critical dose medications. Archives Internal Medicine. 157:1997;2080-2088
26. Bearden W.O., Mason J.B., Smith E.M. Perceived risk and elderly perceptions of generic drug prescribing. Gerontologist. 19:1979;191-195
27. Prosser H., Almond S., Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Family Practice. 20:2003;61-68
28. McGettigan P., Golden J., Fryer J., Chan R., Feely J. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. British Journal of Clinical Pharmacology. 51:2001;184-189
29. Jones M.I., Greenfield S.M., Bradley C.P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 323:2001;378-381
30. Denig P., Haaijer-Ruskamp F.M., Zijsling D.H. How physicians choose drugs. Social Science & Medicine. 27:1988;1381-1386
31. Roberts S.J., Bateman D.N., Smith J.M. Prescribing behaviour in general practice: the impact of promoting therapeutically equivalent cheaper medicines. British Journal of Genetics and Practice. 47:1997;13-18
32. Hammersley V., Hippisley-Cox J., Wilson A., Pringle M. A comparison of research general practices and their patients with other practices - a cross-sectional survey in Trent. British Journal of Genetics and Practice. 52:2002;463-468
33. Hudson J. Generic take-up in the pharmaceutical market following patent expiry. A multi-country study. International Review of Law and Economics. 20:2000;205-221
34. Peay M.Y., Peay E.R. Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. Social Science & Medicine. 18:1984;1019-1025
35. Scott Morton F.M. Bariers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization. 18:2000;1085-1104
36. Hemminki E. Review of literature on the factors affecting drug prescribing. Social Science & Medicine. 9:1967;111-115
37. Weiss M., Fitzpatrick R. Challenges to medicine: the case of prescribing. Sociology of Health and Illness. 19:1997;297-327
38. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. Rand Journal of Economics. 29:1998;108-136
39. Stevenson F.A. General practitioners' views on shared decision making: a qualitative analysis. Patient Education Counsels. 50:2003;291-293
40. Stevenson F.A., Barry C.A., Britten N., Barber N., Bradley C.P. Doctor-patient communication about drugs: the evidence for shared decision making. Social Science & Medicine. 50:2000;829-840
41. Scott A., Shiell A., King M. Is general practitioner decision making associated with patient socio-economic status. Social Science & Medicine. 42:1996;35-46
42. Lundin D. Moral hazard in physician prescription behavior. Journal of Health and Economics. 19:2000;639-662
43. Huttin C., Andral J. How the reimbursement system may influence physicians' decisions results from focus groups interviews in France. Health Policy. 54:2000;67-86
44. Hellerstein JK. The demand for post-patent prescription pharmaceuticals. NBER Working Paper 1994.
45. Stevenson F.A., Greenfield S.M., Jones M., Nayak A., Bradley C.P. GPs' perceptions of patient influence on prescribing. Family Practice. 16:1999;255-261
46. Dowell J.S., Snadden D., Dunbar J.A. Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ. 310:1995;505-508
47. Dowell J.S., Snadden D., Dunbar J.A. Rapid prescribing change, how do patients respond? Social Science & Medicine. 43:1996;1543-1549
48. Valles J.A., Barreiro M., Cereza G., Ferro J.J., Martinez M.J., Escriba J.M., et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy. 65:2003;269-275
49. Ministère de la Santé de la Famille et des Personnes Handicapées. Les médicaments génériques: tout le monde y gagne. Ministère de la Santé, de la Famille et des Personnes Handicapées, Paris, 2003.
50. Stern S, Trajtenberg M. Empirical implications of physician authority in pharmaceutical decision making. 1998. NBER Working Paper 6851, Cambridge.
51. Scott A., Shiell A. Do fee descriptors influence treatment choices in general practice? A multilevel discrete choice model. Journal of Health Economics. 16:1997;323-342
52. Keith L.G., Oleszczuk J.J., Ahranjani M. A critical assessment of generic substitution for the obstetrician-gynecologist. International Journal of Fertilisation of Womens Medicine. 46:2001;286-295
53. Lesser R.P., Krauss G. Buy some today: can generics be safely substituted for brand-name drugs? Neurology. 57:2001;571-573
54. Healey A.T., Yule B.F., Reid J.P. Variations in general practice prescribing costs and implications for budget setting. Health Economics. 3:1994;47-56